Brontictuzumab
- Product Name
- Brontictuzumab
- CAS No.
- 1447814-75-6
- Chemical Name
- Brontictuzumab
- Synonyms
- Brontictuzumab;Brontictuzumab (anti-NOTCH1);Research Grade Brontictuzumab;Research Grade Brontictuzumab(DHE48301)
- CBNumber
- CB08080903
- Formula Weight
- 0
- MOL File
- Mol file
Brontictuzumab Property
- form
- Liquid
- color
- Colorless to light yellow
N-Bromosuccinimide Price
- Product number
- SLK-A2681
- Product name
- Brontictuzumab (Anti-NOTCH1)
- Packaging
- 1mg
- Price
- $447
- Updated
- 2026/05/26
- Product number
- SLK-A2681
- Product name
- Brontictuzumab (Anti-NOTCH1)
- Packaging
- 1mg*5
- Price
- $1321
- Updated
- 2026/05/26
- Product number
- SLK-A2681
- Product name
- Brontictuzumab (Anti-NOTCH1)
- Packaging
- 1mg*25
- Price
- $3962
- Updated
- 2026/05/26
- Product number
- HY-P99258
- Product name
- Brontictuzumab
- Purity
- 95.00%
- Packaging
- 1mg
- Price
- $428
- Updated
- 2026/05/26
- Product number
- HY-P99258
- Product name
- Brontictuzumab
- Purity
- 95.00%
- Packaging
- 5mg
- Price
- $1112
- Updated
- 2026/05/26
Brontictuzumab Chemical Properties,Usage,Production
Uses
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma[1][2][3].
in vivo
Brontictuzumab (15 mg/kg, i.p.) reduces tumor burden in T-ALL xenograft[3].
Brontictuzumab (20 mg/kg, i.p., every 4days) inhibits DLL4 induced activation of Notch1 in MCL model[2].
| Animal Model: | T-ALL xenograft[3] |
| Dosage: | 15 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), twice weekly. |
| Result: | Inhibited tumor growth and reduced the size of the spleen. Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells. |
| Animal Model: | NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo[2] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth. |
References
[1] Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568. DOI:10.1093/annonc/mdy171
[2] Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446. DOI:10.1186/s13046-019-1458-7
[3] Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28(2):278-88. DOI:10.1038/leu.2013.183
Brontictuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Brontictuzumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 89686
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7999
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310 15002144251
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24955
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9865
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 7081
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11972
- Advantage
- 58
- Tel
- 027-027-16602739303 16602739303
- 673003916@qq.com
- Country
- China
- ProdList
- 4565
- Advantage
- 58
- Tel
- 15111215862 18229892877
- 3062105966@qq.com
- Country
- China
- ProdList
- 5432
- Advantage
- 58